Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Fate Therapeutics Inc

NASDAQ: FATE · Life Sciences · 4 alerts · CIK 1434316

Share price
$1.14Close, Nov 16
Market cap
$139M
Shares outstanding
121.57MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Fate Therapeutics Inc filings on SEC EDGAR ↗

8:11 AM ET 8-K
Business Update

Fate Therapeutics Business Update

Fate Therapeutics was awarded a $15 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to support its Phase 2 RECLAIM-LN clinical trial. The funding will advance the development of FT819, an off-the-shelf CAR T-cell therapy for patients with refractory lupus nephritis, a severe manifestation of systemic lupus erythematosus.

Counterparty
California Institute for Regenerative Medicine (CIRM)

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.